Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report

Bruce Shiramizu, Stanton Goldman, Lynette Smith, Melissa Agsalda-Garcia, Paul Galardy, Sherrie L. Perkins, J. Kimble Frazer, Warren Sanger, James R. Anderson, Thomas G. Gross, Howard Weinstein, Lauren Harrison, Matthew J. Barth, Lara Mussolin, Mitchell S. Cairo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.

Original languageEnglish (US)
Pages (from-to)367-371
Number of pages5
JournalBritish Journal of Haematology
Volume170
Issue number3
DOIs
StatePublished - 2015

Fingerprint

Burkitt Lymphoma
Residual Neoplasm
Therapeutics
Recurrence
Central Nervous System Diseases
Real-Time Polymerase Chain Reaction
Bone Marrow

Keywords

  • central nervous system
  • children
  • leukaemia

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia : a Children's Oncology Group Pilot Study Report. / Shiramizu, Bruce; Goldman, Stanton; Smith, Lynette; Agsalda-Garcia, Melissa; Galardy, Paul; Perkins, Sherrie L.; Frazer, J. Kimble; Sanger, Warren; Anderson, James R.; Gross, Thomas G.; Weinstein, Howard; Harrison, Lauren; Barth, Matthew J.; Mussolin, Lara; Cairo, Mitchell S.

In: British Journal of Haematology, Vol. 170, No. 3, 2015, p. 367-371.

Research output: Contribution to journalArticle

Shiramizu, B, Goldman, S, Smith, L, Agsalda-Garcia, M, Galardy, P, Perkins, SL, Frazer, JK, Sanger, W, Anderson, JR, Gross, TG, Weinstein, H, Harrison, L, Barth, MJ, Mussolin, L & Cairo, MS 2015, 'Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report', British Journal of Haematology, vol. 170, no. 3, pp. 367-371. https://doi.org/10.1111/bjh.13443
Shiramizu, Bruce ; Goldman, Stanton ; Smith, Lynette ; Agsalda-Garcia, Melissa ; Galardy, Paul ; Perkins, Sherrie L. ; Frazer, J. Kimble ; Sanger, Warren ; Anderson, James R. ; Gross, Thomas G. ; Weinstein, Howard ; Harrison, Lauren ; Barth, Matthew J. ; Mussolin, Lara ; Cairo, Mitchell S. / Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia : a Children's Oncology Group Pilot Study Report. In: British Journal of Haematology. 2015 ; Vol. 170, No. 3. pp. 367-371.
@article{85a4fef76cab49b8853a4f76f33d9eaa,
title = "Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report",
abstract = "Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71{\%} (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.",
keywords = "central nervous system, children, leukaemia",
author = "Bruce Shiramizu and Stanton Goldman and Lynette Smith and Melissa Agsalda-Garcia and Paul Galardy and Perkins, {Sherrie L.} and Frazer, {J. Kimble} and Warren Sanger and Anderson, {James R.} and Gross, {Thomas G.} and Howard Weinstein and Lauren Harrison and Barth, {Matthew J.} and Lara Mussolin and Cairo, {Mitchell S.}",
year = "2015",
doi = "10.1111/bjh.13443",
language = "English (US)",
volume = "170",
pages = "367--371",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia

T2 - a Children's Oncology Group Pilot Study Report

AU - Shiramizu, Bruce

AU - Goldman, Stanton

AU - Smith, Lynette

AU - Agsalda-Garcia, Melissa

AU - Galardy, Paul

AU - Perkins, Sherrie L.

AU - Frazer, J. Kimble

AU - Sanger, Warren

AU - Anderson, James R.

AU - Gross, Thomas G.

AU - Weinstein, Howard

AU - Harrison, Lauren

AU - Barth, Matthew J.

AU - Mussolin, Lara

AU - Cairo, Mitchell S.

PY - 2015

Y1 - 2015

N2 - Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.

AB - Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.

KW - central nervous system

KW - children

KW - leukaemia

UR - http://www.scopus.com/inward/record.url?scp=84964696036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964696036&partnerID=8YFLogxK

U2 - 10.1111/bjh.13443

DO - 10.1111/bjh.13443

M3 - Article

C2 - 25858645

AN - SCOPUS:84964696036

VL - 170

SP - 367

EP - 371

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -